THE SETPOINT STUDY: DOES EARLY THERAPY ALTER THE VIROLOGIC SETPOINT?

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究的目的是了解在早期艾滋病毒感染期间治疗是否有益。 本研究将评估抗HIV药物（恩曲他滨/替诺福韦DF和洛匹那韦/利托那韦）组合对近期获得性HIV感染者的安全性和有效性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to learn if treating people during early HIV infection is beneficial. This study will evaluate how safe and effective a combination of anti-HIV drugs (emtricitabine/Tenofovir DF and Lopinavir/Ritonavir) is for people with recently acquired HIV infection.